CANTON, Mass.--(BUSINESS WIRE)--Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback